Fisher & Paykel Healthcare upgrades FY26 earnings outlook

The Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) share price is in focus after the company upgraded its FY26 revenue guidance to approximately $2.30 billion and lifted its net profit outlook.

What did Fisher & Paykel Healthcare report?

• Full-year FY26 operating revenue now expected to be around $2.30 billion (previously $2.17–$2.27 billion)
• Net profit after tax (NPAT) raised to between $450 million and $470 million (previously $410 million–$460 million)
• Guidance assumes NZ:US exchange rate of 60 cents as at 31 January 2026
• Updated figures do not include any potential US tariff refunds

What else do investors need to know?

Fisher & Paykel Healthcare reported strong growth across its full range of Hospital products, contributing to the upgraded guidance. The company noted ongoing improvements in gross margin and operating margin, supported by efficiency gains and continuous improvement activities.

A major regulatory update came as the United States Supreme Court overturned tariffs imposed under the IEEPA, but Fisher & Paykel Healthcare continues to work through the refund process and potential implications. Management expects to provide a further update on any tariff impacts with the full-year results in May.

What did Fisher & Paykel Healthcare management say?

Managing Director and CEO Lewis Gradon said:

We have continued to see good growth across the full range of our Hospital products so far during our second half.

Continuous improvement activities and other efficiency gains are also contributing to improvements in our gross margin and operating margin.

What’s next for Fisher & Paykel Healthcare?

Looking ahead, management will provide more detail on tariff developments and possible refunds when announcing its full-year results. The company remains confident that cost increases from tariffs will be mitigated over time by ongoing efficiency efforts.

Fisher & Paykel Healthcare continues to focus on innovation, expanding its footprint in respiratory care, and driving sustainable, profitable growth. The company maintains that the long-term strategy and direction are unchanged.

Fisher & Paykel Healthcare share price snapshot

Over the past 12 months, Fisher & Paykel shares have risen 2%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Fisher & Paykel Healthcare upgrades FY26 earnings outlook appeared first on The Motley Fool Australia.

More reading

• Reece HY26 results: Profit falls despite higher sales revenue
• Chorus half-year earnings: Profit growth and higher fibre uptake
• 5 things to watch on the ASX 200 on Monday
• ASX 200 tech shares lead market sectors with a 7% bounce back
• Could you retire at 60 with the average superannuation balance?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.